• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

    12/11/25 8:30:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    • Data shared in collaboration with The University of Texas Medical Branch, representing an analysis of more than one million intravenous (IV) infusions using Baxter's Spectrum IQ large volume infusion pumps (LVP)
    • Evaluation of pre- and post-smart pump EMR integration data showed a reduction in patient safety alerts, time spent to program an infusion and to resolve a pump alert
    • Findings underscore the potential role of connected infusion therapy in supporting patient safety, addressing clinician burnout and compliance

    Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medical Branch (UTMB Health) demonstrating the positive impact of smart infusion pump integration with hospital electronic medical records (EMRs) on patient safety, clinicians' bedside productivity and programming compliance. The analyses of more than one million infusions on Baxter's Spectrum IQ large volume infusion pumps (LVP) at UTMB were presented at the American Society of Health-System Pharmacists (ASHP) 2025 Midyear Clinical Meeting, held Dec. 7 – Dec. 10, 2025.

    "Health systems face mounting challenges, from resource shortages to staff fatigue, yet remain committed to delivering the highest standards of care," said Jay Ehrlich, MD, vice president of global patient safety and clinical research at Baxter. "Baxter is proud to provide technologies that help address these priorities and foster ongoing quality improvement initiatives to help advance patient safety and address cognitive overload for clinicians. The findings presented at ASHP, developed in collaboration with the University of Texas Medical Branch, reinforce the potential broad impact of, and opportunities associated with, smart infusion pump EMR integration."

    Intravenous (IV) medication errors remain a common yet often preventable cause of patient harm.i, ii Smart infusion pump capabilities like auto-programming, which is enabled through EMR integration, and dose-error reduction systems (DERS), which help prevent medication errors by checking programmed doses against preset drug-specific soft and hard limits, help support safer medication administration and offer the opportunity to help minimize manual tasks and reduce cognitive burden for nurses at the bedside.iii, iv

    The information presented at ASHP leverages retrospectively collected data of 1.3 million infusions using Baxter's Spectrum IQ LVP at six UTMB hospitals over a three-year period. The data was analyzed and compared based on EMR integration status, care area and infusion programming type (e.g., manual vs. auto-programming). In addition to improved DERS and auto-programming compliance after EMR integration, key findings include:

    • Patient Safety: Following EMR integration, all evaluated safety alerts for infusions decreased in frequency, with DERS hard limit alerts decreasing by 50.3%, soft limit alerts by 30.4% and single step rate change (SSRC) alerts -- a safety feature unique to Baxter's infusion pump portfolio -- by 38.1%, implying that more programmed doses were within the drug library limits.v These alert types were also substantially less frequent when comparing auto-programmed to manually programmed infusions, likely due to the avoidance of manual programming errors. The data also suggests that drug library optimization with use of auto-programming resulted in fewer required interventions.
    • Clinician Productivity: EMR integration-enabled auto-programming utilizes streamlined sequential bar code scanning compared to manual keypad entry for manually programmed infusions. Post EMR-integration, the use of auto-programming required fewer steps than manual programming and also reduced median time to program an infusion from 10 seconds to four seconds. In cases where the pump issued a programming alert in the post-integration phase, the average time to address soft limit alerts decreased by nearly 50%, while single step rate change alert resolution time dropped by 55%.

    "Integrating smart infusion pumps with our EMR is more than a technology upgrade—it's a commitment to safer, more efficient care at the bedside. This collaboration helps our clinicians spend less time troubleshooting and more time focusing on patients," said Juanita Norton, PhD, MBA, MSN, CPHQ, RN-BC, CPN, CLSSBB, program manager, quality improvement, The University of Texas Medical Branch.

    These findings help address two critical priorities for health systems: reducing preventable safety alerts and alleviating clinician workload. By demonstrating a measurable reduction in safety limit alerts and workflow improvements, this analysis underscores how smart pump EMR integration, with DERS and auto-programming, may help health systems deliver safer, more efficient care. Learn more about the data presented at ASHP here.

    About Baxter

    At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 38,000 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    About The University of Texas Medical Branch (UTMB)

    The first academic health center in Texas opened its doors in 1891 and today has four campuses, five health sciences schools, seven institutes for advanced study, a research enterprise that includes one of only two national laboratories dedicated to the safe study of infectious threats to human health, a Level 1 Trauma Center and a health system offering a full range of primary and specialized medical services throughout the Texas Gulf Coast region. UTMB is an institution in The University of Texas System and a member of the Texas Medical Center.

    Rx Only. For safe and proper use of this device, refer to the full Instructions for Use.

    INDICATIONS

    The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used for the controlled administration of fluids. These may include pharmaceutical drugs, blood, and blood products. The intended routes of administration consist of the following clinically accepted routes: IV, arterial, subcutaneous, or epidural. The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used in conjunction with legally marketed and compatible IV administration sets and medications provided by the user. The Spectrum IQ Infusion System with Dose IQ Safety Software is suitable for a variety of patient care environments such as, but not limited to, hospitals and outpatient care areas. The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to reduce operator interaction through guided programming, including a way to automate the programming of infusion parameters and documentation of infusion therapies. This automation is intended to reduce pump programming errors. The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used by trained healthcare professionals.

    This release includes forward-looking statements concerning potential benefits associated with Spectrum IQ LVP. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand and market acceptance for, and competitive pressures (including pricing) related to, new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, war, terrorism, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

    Baxter and Spectrum IQ are registered trademarks of Baxter International Inc.

    _________________________________

    i UC Davis PET. Medication Errors and Adverse Drug Events. PSNet [internet]. Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2024. https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events

     

    ii Skog J, Rafie S, Schnock KO, Yoon C, Lipsitz S, Lew P. The Impact of Smart Pump Interoperability on Errors in Intravenous Infusion Administrations: A Multihospital Before and After Study. J Patient Saf. Apr 1 2022;18(3):e666-e671. doi:10.1097/PTS.0000000000000905

     

    iii ISMP. Guidelines for Optimizing Safe Implementation and Use of Smart Infusion Pumps. 2020. https://www.ismp.org/system/files/resources/2020-10/ISMP176C-Smart%20Infusion%20Pumps-100620.pdf

     

    iv Schnock KO, Dykes PC, Albert J, et al. The frequency of intravenous medication administration errors related to smart infusion pumps: a multihospital observational study. BMJ Qual Saf. Feb 2017;26(2):131-140. doi:10.1136/bmjqs-2015-004465

     

    v Data on file at Baxter International Inc.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251211779123/en/

    Media Contact

    Brenna Byrne, (224) 948-5353

    [email protected]

    Investor Contact

    Kevin Moran, (224) 948-3085

    [email protected]

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    More analyst ratings

    $BAX
    SEC Filings

    View All

    Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    12/4/25 4:15:43 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/25/25 4:45:37 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form FWP filed by Baxter International Inc.

    FWP - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/19/25 5:17:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Soriano Maria Cecilia claimed ownership of 54,623 shares (SEC Form 3)

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    12/10/25 9:18:08 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Baxter International Inc.

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    12/3/25 4:04:17 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP,Group President,Pharma Sonig Alok covered exercise/tax liability with 3,191 shares, decreasing direct ownership by 2% to 128,219 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:02:32 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

    Data shared in collaboration with The University of Texas Medical Branch, representing an analysis of more than one million intravenous (IV) infusions using Baxter's Spectrum IQ large volume infusion pumps (LVP) Evaluation of pre- and post-smart pump EMR integration data showed a reduction in patient safety alerts, time spent to program an infusion and to resolve a pump alert Findings underscore the potential role of connected infusion therapy in supporting patient safety, addressing clinician burnout and compliance Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medi

    12/11/25 8:30:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    INVESTIGATION ALERT: Berger Montague PC Investigates Baxter International Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: BAX)

    PHILADELPHIA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Baxter International Inc. ("Baxter" or the "Company") (NYSE:BAX) about an investigation into Baxter's Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter's marketing and sale of its Novum Large Volume Pump ("Novum LVP"). Shareholders of Baxter may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) 875-3015, or CLICK HERE. Berger Montague's investigation is focused on whether Baxter's Bo

    12/4/25 11:12:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amended by the Company's press release dated Nov. 19, 2025 (as it may be further amended or supplemented from time to time, the "Offer to Purchase"). The tender offers comprise Baxter's offer to purchase for cash (a) any and all of its 2.600% senior unsecured notes due 2026 (the "2026 Notes") (the "Any and All Tender Offer") and (b) a portion of its 1.9

    12/4/25 7:51:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care